Patent ID: 9713612
Date: 2017-07-25
CPC Classifications: A61K,A61P

Claim:
1. A method for treating cancer characterized by expression of an R-spondin fusion in a subject that has been diagnosed as having an R-spondin fusion and has been diagnosed with the cancer being treated, comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein X X Y Y R C 6-30 aryl, 3 to 6 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from N, O and S, or 5 or 6 membered heteroaryl containing 1 to 4 heteroatoms selected from N, O and S, wherein each of quinolinyl, C 6-30 aryl, 3 to 6 membered heterocycloalkyl, and 5 or 6 membered heteroaryl can be optionally substituted with one or two, and same or different R 4 ; R C 6-30 aryl, 3 to 6 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from N, O and S, or 5 or 6 membered heteroaryl containing 1 to 4 heteroatoms selected from N, O and S, wherein each of quinolinyl, C 6-30 aryl, 3 to 6 membered heterocycloalkyl, and 5 or 6 membered heteroaryl can be optionally substituted with one or two, and same or different R 4 ; each R each R R wherein the core structure defined by X